drugset / Trial / NCT00717587
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
Phase 2
Unknown
20 enrolled
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well sunitinib works when given before and after surgery in treating patients with stage IV kidney cancer.
Timeline
- Start
- 2008-06
- Primary completion
- 2010-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunitinib | Small molecule | — | Oral |
| Background | motexafin gadolinium | Diagnostic / imaging agent | — | — |